Experimental Drugs for Chemotherapy- and Cancer-Related Anemia

References

• McLean E, Cogswell M, Egli I, Wojdyla D, de Benoist B. Worldwide prevalence of anaemia, WHO vitamin and mineral nutrition information system, 1993–2005. Public Health Nutr. 2009;12(4):444–454. doi:10.1017/S1368980008002401
   PubMed Web of Science ®Google Scholar
• Madeddu C, Gramignano G, Astara G, et al. Pathogenesis and treatment options of cancer related anemia: perspective for a targeted mechanism-based approach. Front Physiol. 2018;9:1294. doi:10.3389/fphys.2018.01294
   PubMed Web of Science ®Google Scholar
• Birgegård G, Aapro MS, Bokemeyer C, et al. Cancer-related anemia: pathogenesis, prevalence and treatment. Oncology. 2005;68(Suppl 1):3–11. doi:10.1159/000083128
   PubMed Web of Science ®Google Scholar
• Schwartz RN. Anemia in patients with cancer: incidence, causes, impact, management, and use of treatment guidelines and protocols. Am J Health Syst Pharm. 2007;64(3Suppl 2):S5–S13;quiz S28–S30. doi:10.2146/ajhp060601
   Web of Science ®Google Scholar
• Wu Y, Aravind S, Ranganathan G, Martin A, Nalysnyk L. Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: a descriptive study of a large outpatient oncology practice database, 2000–2007. Clin Ther. 2009;31(Pt 2):2416–2432. doi:10.1016/j.clinthera.2009.11.020
   PubMed Web of Science ®Google Scholar
• Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med. 2004;116(Suppl7A):11S–26S. doi:10.1016/j.amjmed.2003.12.008
   Web of Science ®Google Scholar
• Melo-Alvim C, Miguel-Semedo P, Paiva RS, et al. Pretreatment hemoglobin level as a prognostic factor in patients with locally advanced head and neck squamous cell carcinoma. Rep Pract Oncol Radiother. 2020;25(5):768–774. doi:10.1016/j.rpor.2020.07.002
   Google Scholar
• An MS, Yoo JH, Kim KH, et al. T4 stage and preoperative anemia as prognostic factors for the patients with colon cancer treated with adjuvant FOLFOX chemotherapy. World J Surg Oncol. 2015;13:64. doi:10.1186/s12957-015-0488-7
   PubMed Web of Science ®Google Scholar
• Shin NR, Lee YY, Kim SH, et al. Prognostic value of pretreatment hemoglobin level in patients with early cervical cancer. Obstet Gynecol Sci. 2014;57(1):28–36. doi:10.5468/ogs.2014.57.1.28
   PubMedGoogle Scholar
• Zhang Y, Chen Y, Chen D, et al. Impact of preoperative anemia on relapse and survival in breast cancer patients. BMC Cancer. 2014;14:844. doi:10.1186/1471-2407-14-844
   PubMed Web of Science ®Google Scholar
• Obermair A, Petru E, Windbichler G, et al. Significance of pretreatment serum hemoglobin and survival in epithelial ovarian cancer. Oncol Rep. 2000;7:639–644. doi:10.3892/or.7.3.639
   Web of Science ®Google Scholar
• Lee WR, Berkey B, Marcial V, et al. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27. Int J Radiat Oncol Biol Phys. 1998;42(5):1069–1075. doi:10.1016/S0360-3016(98)00348-4
   Web of Science ®Google Scholar
• Grant DG, Hussain A, Hurman D. Pre-treatment anaemia alters outcome in early squamous cell carcinoma of the larynx treated by radical radiotherapy. J Laryngol Otol. 1999;113(9):829–833. doi:10.1017/S0022215100145323
   Web of Science ®Google Scholar
• Prosnitz RG, Yao B, Farrell CL, Clough R, Brizel DM. Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 2005;61(4):1087–1095. doi:10.1016/j.ijrobp.2004.07.710
   PubMed Web of Science ®Google Scholar
• Fuso L, Mazzola S, Marocco F, et al. Pretreatment serum hemoglobin level as a predictive factor of response to neoadjuvant chemotherapy in patients with locally advanced squamous cervical carcinoma: a preliminary report. Gynecol Oncol. 2005;99(3 Suppl 1):S187–S191. doi:10.1016/j.ygyno.2005.07.079
   PubMed Web of Science ®Google Scholar
• Zhu W, Xu B. Association of pretreatment anemia with pathological response and survival of breast cancer patients treated with neoadjuvant chemotherapy: a population-based study. PLoS One. 2015;10(8):e0136268. doi:10.1371/journal.pone.0136268
   PubMed Web of Science ®Google Scholar
• Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2(1):38–47. doi:10.1038/nrc704
   PubMed Web of Science ®Google Scholar
• Holzner B, Kemmler G, Greil R, et al. The impact of hemoglobin levels on fatigue and quality of life in cancer patients. Ann Oncol. 2002;13(6):965–973. doi:10.1093/annonc/mdf122
   PubMed Web of Science ®Google Scholar
• Ludwig H, Müldür E, Endler G, Hübl W. Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia. Ann Oncol. 2013;24(7):1886–1892. doi:10.1093/annonc/mdt118
   PubMed Web of Science ®Google Scholar
• Owusu C, Cohen HJ, Feng T, et al.; Cancer and Aging Research Group (CARG). Anemia and functional disability in older adults with cancer. J Natl Compr Canc Netw. 2015;13(10):1233–1239. doi:10.6004/jnccn.2015.0152
   Web of Science ®Google Scholar
• Spivak JL. Cancer-related anemia: its causes and characteristics. Semin Oncol. 1994;21(2 Suppl 3):3–8.
   PubMed Web of Science ®Google Scholar
• Adamson JW. The anemia of inflammation/malignancy: mechanisms and management. Hematol Am Soc Hematol Educ Program. 2008;2008(1):159–165. doi:10.1182/asheducation-2008.1.159
   Google Scholar
• Spivak JL. The anaemia of cancer: death by a thousand cuts. Nat Rev Cancer. 2005;5(7):543–555. doi:10.1038/nrc1648
   Web of Science ®Google Scholar
• Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med. 1990;322(24):1689–1692. doi:10.1056/NEJM199006143222401
   PubMed Web of Science ®Google Scholar
• Aapro M, Österborg A, Gascón P, Ludwig H, Beguin Y. Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron. Ann Oncol. 2012;23(8):1954–1962. doi:10.1093/annonc/mds112
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Hematopoietic Growth Factors. Version 2; March 23, 2021. Available from: https://www.nccn.org/professionals/physician_gls/pdf/growthfactors.pdf. Accessed April 13, 2021.
   Google Scholar
• Spivak JL. Iron and the anemia of chronic disease. Oncology (Huntingt). 2002;16(9 Suppl 10):25–33.
   Web of Science ®Google Scholar
• Faquin WC, Schneider TJ, Goldberg MA. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood. 1992;79(8):1987–1994. doi:10.1182/blood.V79.8.1987.1987
   PubMed Web of Science ®Google Scholar
• Jewell UR, Kvietikova I, Scheid A, Bauer C, Wenger RH, Gassmann M. Induction of HIF-1 alpha in response to hypoxia is instantaneous. FASEB J. 2001;15(7):1312–1314. doi:10.1096/fj.00-0732fje
   PubMed Web of Science ®Google Scholar
• Lang F, Abed M, Lang E, Föller M. Oxidative stress and suicidal erythrocyte death. Antioxid Redox Signal. 2014;21(1):138–153. doi:10.1089/ars.2013.5747
   PubMed Web of Science ®Google Scholar
• Macciò A, Madeddu C, Gramignano G, et al. The role of inflammation, iron, and nutritional status in cancer-related anemia: results of a large, prospective, observational study. Haematologica. 2015;100(1):124–132. doi:10.3324/haematol.2014.112813
   PubMed Web of Science ®Google Scholar
• Andrews NC. Anemia of inflammation: the cytokine-hepcidin link. J Clin Invest. 2004;113(9):1251–1253. doi:10.1172/JCI21441
   PubMed Web of Science ®Google Scholar
• Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 2003;102(3):783–788. doi:10.1182/blood-2003-03-0672
   PubMed Web of Science ®Google Scholar
• Macciò A, Madeddu C, Gramignano G, et al. A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life. Gynecol Oncol. 2012;124(3):417–425. doi:10.1016/j.ygyno.2011.12.435
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0; November 27, 2017. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf. Accessed February 02, 2021.
   Google Scholar
• Dalton JD, Bailey NP, Barrett-Lee PJ, O’Brien MER. Multicenter UK audit of anemia in patients receiving cytotoxic chemotherapy [abstract]. Proc ASCO. 1998;17:418a.
   Google Scholar
• Cheng K, Zhao F, Gao F, et al. Factors potentially associated with chemotherapy-induced anemia in patients with solid cancers. Asian Pac J Cancer Prev. 2012;13(10):5057–5061. doi:10.7314/APJCP.2012.13.10.5057
   Google Scholar
• Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst. 1999;91(19):1616–1634. doi:10.1093/jnci/91.19.1616
   PubMed Web of Science ®Google Scholar
• Perazella MA, Moeckel GW. Nephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention/therapy. Semin Nephrol. 2010;30(6):570–581. doi:10.1016/j.semnephrol.2010.09.005
   PubMed Web of Science ®Google Scholar
• Neumcke I, Schneider B, Fandrey J, Pagel H. Effects of pro- and antioxidative compounds on renal production of erythropoietin. Endocrinology. 1999;140(2):641–645. doi:10.1210/endo.140.2.6529
   Web of Science ®Google Scholar
• Macciò A, Madeddu C. Cisplatin: an old drug with a newfound efficacy - from mechanisms of action to cytotoxicity. Expert Opin Pharmacother. 2013;14(13):1839–1857. doi:10.1517/14656566.2013.813934
   PubMed Web of Science ®Google Scholar
• Barni S, Cabiddu M, Guarneri P, Lonati V, Petrelli F. The risk for anemia with targeted therapies for solid tumors. Oncologist. 2012;17(5):715–724. doi:10.1634/theoncologist.2012-0024
   PubMed Web of Science ®Google Scholar
• Ruiz-Schutz VC, Gomes LM, Mariano RC, et al. Risk of fatigue and anemia in patients with advanced cancer treated with olaparib: a meta-analysis of randomized controlled trials. Crit Rev Oncol Hematol. 2019;141:163–173. doi:10.1016/j.critrevonc.2019.06.012
   PubMed Web of Science ®Google Scholar
• Moore KN, Mirza MR, Matulonis UA. The poly (ADP ribose) polymerase inhibitor niraparib: management of toxicities. Gynecol Oncol. 2018;149(1):214–220. doi:10.1016/j.ygyno.2018.01.011
   PubMed Web of Science ®Google Scholar
• Wahlberg E, Karlberg T, Kouznetsova E, et al. Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors. Nat Biotechnol. 2012;30(3):283–288. doi:10.1038/nbt.2121
   PubMed Web of Science ®Google Scholar
• Farrés J, Martín-Caballero J, Martínez C, et al. Parp-2 is required to maintain hematopoiesis following sublethal γ-irradiation in mice. Blood. 2013;122(1):44–54. doi:10.1182/blood-2012-12-472845
   PubMed Web of Science ®Google Scholar
• Farrés J, Llacuna L, Martin-Caballero J, et al. PARP-2 sustains erythropoiesis in mice by limiting replicative stress in erythroid progenitors. Cell Death Differ. 2015;22(7):1144–1157. doi:10.1038/cdd.2014.202
   PubMed Web of Science ®Google Scholar
• Pelham C, Jimenez T, Rodova M, Rudolph A, Chipps E, Islam MR. Regulation of HFE expression by poly(ADP-ribose) polymerase-1 (PARP1) through an inverted repeat DNA sequence in the distal promoter. Biochim Biophys Acta. 2013;1829(12):1257–1265. doi:10.1016/j.bbagrm.2013.10.002
   Web of Science ®Google Scholar
• Gao F, Cheng K, Zhao F, et al. Prevalence and characteristics of anemia in patients with solid cancers at diagnosis in southwest China. Asian Pac J Cancer Prev. 2011;12(11):2825–2828.
   Google Scholar
• Ganz T. Anemia of inflammation. N Engl J Med. 2019;381(12):1148–1157. doi:10.1056/NEJMra1804281
   PubMed Web of Science ®Google Scholar
• Macciò A, Madeddu C, Massa D, et al. Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia. Blood. 2005;106(1):362–367. doi:10.1182/blood-2005-01-0160
   PubMed Web of Science ®Google Scholar
• Gilreath JA, Rodgers GM. How I treat cancer-associated anemia. Blood. 2020;136(7):801–813. doi:10.1182/blood.2019004017
   PubMed Web of Science ®Google Scholar
• Proctor MJ, Morrison DS, Talwar D, et al. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br J Cancer. 2011;104(4):726–734. doi:10.1038/sj.bjc.6606087
   PubMed Web of Science ®Google Scholar
• Crawford J, Cella D, Cleeland CS, et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer. 2002;95(4):888–895. doi:10.1002/cncr.10763
   PubMed Web of Science ®Google Scholar
• Davies KJ, Maguire JJ, Brooks GA, Dallman PR, Packer L. Muscle mitochondrial bioenergetics, oxygen supply, and work capacity during dietary iron deficiency and repletion. Am J Physiol. 1982;242(6):E418–E427. doi:10.1152/ajpendo.1982.242.6.E418
   PubMed Web of Science ®Google Scholar
• Poulos TL. Heme enzyme structure and function. Chem Rev. 2014;114(7):3919–3962.
   PubMed Web of Science ®Google Scholar
• Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352(10):1011–1023. doi:10.1056/NEJMra041809
   PubMed Web of Science ®Google Scholar
• Carson JL, Grossman BJ, Kleinman S, et al. Red blood cell transfusion: a clinical practice guideline from the AABB. Ann Intern Med. 2012;157(1):49–58. doi: 10.7326/0003-4819-157-1-201206190-00429
   Google Scholar
• Mercadante S, Ferrara P, Villari P, David F, Giarratano A, Riina S. Effects of red blood transfusion on anemia-related symptoms in patients with cancer. J Palliat Med. 2009;12(1):60–63. doi:10.1089/jpm.2008.0139
   Web of Science ®Google Scholar
• Callum JL, Waters JH, Shaz BH, Sloan SR, Murphy MF. The AABB recommendations for the choosing wisely campaign of the American Board of Internal Medicine. Transfusion. 2014;54(9):2344–2352. doi:10.1111/trf.12802
   Web of Science ®Google Scholar
• Aapro M, Chernov VM, Gladkov OA, et al. Practical recommendations for the treatment of anemia in cancer patients. Malignant Tumors. 2016;4:368–377.
   Google Scholar
• Bohlius J, Bohlke K, Castelli R, et al. Management of Cancer-Associated anemia with erythropoiesis-stimulating agents: ASCO/ASH Clinical Practice Guideline Update. J Clin Oncol. 2019;37(15):1336–1351. doi:10.1200/JCO.18.02142
   PubMed Web of Science ®Google Scholar
• Aapro M, Beguin Y, Bokemeyer C, et al.; ESMO Guidelines Committee. Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. Ann Oncol. 2018;29(Suppl 4):iv96–iv110. doi:10.1093/annonc/mdx758
   PubMed Web of Science ®Google Scholar
• Carson JL, Carless PA, Hebert PC. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev. 2018;4(4):CD002042.
   Google Scholar
• Goodnough LT. Risks of blood transfusion. Anesthesiol Clin North Am. 2005;23(2):241–252. doi:10.1016/j.atc.2004.07.004
   PubMedGoogle Scholar
• Khorana AA, Francis CW, Blumberg N, Culakova E, Refaai MA, Lyman GH. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med. 2008;168(21):2377–2381. doi:10.1001/archinte.168.21.2377
   PubMedGoogle Scholar
• Goubran HA, Elemary M, Radosevich M, Seghatchian J, El-Ekiaby M, Burnouf T. Impact of transfusion on cancer growth and outcome. Cancer Growth Metastasis. 2016;9:1–8. doi:10.4137/CGM.S32797
   PubMedGoogle Scholar
• De Oliveira GS Jr, Schink JC, Buoy C, et al. The association between allogeneic perioperative blood transfusion on tumour recurrence and survival in patients with advanced ovarian cancer. Transfus Med. 2012;22(2):97–103. doi:10.1111/j.1365-3148.2011.01122.x
   Web of Science ®Google Scholar
• Youssef LA, Spitalnik SL. Transfusion-related immunomodulation: a reappraisal. Curr Opin Hematol. 2017;24(6):551–557. doi:10.1097/MOH.0000000000000376
   Web of Science ®Google Scholar
• Hedenus M, Adriansson M, San Miguel J, et al.; Darbepoetin Alfa 20000161 Study Group. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol. 2003;122(3):394–403. doi:10.1046/j.1365-2141.2003.04448.x
   PubMed Web of Science ®Google Scholar
• Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B; Epoetin Alfa Study Group. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001;19(11):2865–2874. doi:10.1200/JCO.2001.19.11.2865
   PubMed Web of Science ®Google Scholar
• Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebocontrolled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst. 2002;94(16):1211–1220. doi:10.1093/jnci/94.16.1211
   PubMed Web of Science ®Google Scholar
• Tonia T, Mettler A, Robert N, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. 2012;12:CD003407. doi:10.1002/14651858.CD003407.pub5
   PubMed Web of Science ®Google Scholar
• Bohlius J, Tonia T, Nüesch E, et al. Effects of erythropoiesis-stimulating agents on fatigue- and anaemia-related symptoms in cancer patients: systematic review and meta-analyses of published and unpublished data. Br J Cancer. 2014;111(1):33–45. doi:10.1038/bjc.2014.171
   PubMed Web of Science ®Google Scholar
• Aapro M. An update on twenty years of anemia management with erythropoiesis-stimulating agents in nephrology and oncology/hematology. Oncologist. 2009;14(Suppl 1):1–5. doi:10.1634/theoncologist.2009-S1-1
   PubMed Web of Science ®Google Scholar
• Bohlius J, Weingart O, Trelle S, Engert A. Cancer-related anemia and recombinant human erythropoietin-an updated overview. Nat Clin Pract Oncol. 2006;3(3):152–164. doi:10.1038/ncponc0451
   PubMedGoogle Scholar
• U.S. Food and Drug Administration. Biosimilar and Interchangeable Products; 2017. Available from: https://www.fda.gov/drugs/biosimilars/biosimilar-and-interchangeable-products. Accessed February 06, 2021.
   Google Scholar
• U.S. Food and Drug Administration. Oncologic drugs advisory committee meeting. ‟Epoetin Hospira”, a proposed biosimilar to US-licensed Epogen/Procrit; 2017. Available from: https://www.fda.gov/media/105760/download. Accessed February 06, 2021.
   Google Scholar
• US Food and Drug Administration. FDA approves Retacrit as a biosimilar to Epogen/Procrit. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-retacrit-biosimilar-epogenprocrit. Accesed June 18, 2021.
   Google Scholar
• Smith RE Jr, Aapro MS, Ludwig H, et al. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a Phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol. 2008;26(7):1040–1050. doi:10.1200/JCO.2007.14.2885
   PubMed Web of Science ®Google Scholar
• Gordon D, Nichols G, Ben‐Jacob A, Tomita D, Lillie T, Miller C. Treating anemia of cancer with every‐4‐week darbepoetin alfa: final efficacy and safety results from a Phase II, Randomized, Double‐Blind, Placebo‐Controlled Study. Oncologist. 2008;13(6):715–724. doi:10.1634/theoncologist.2007-0241
   Web of Science ®Google Scholar
• Grant MD, Piper M, Bohlius J, et al. Epoetin and darbepoetin for managing anemia in patients undergoing cancer treatment: comparative effectiveness update [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013. Report No.:13-EHC077-EF.
   Google Scholar
• Tonelli M, Hemmelgarn B, Reiman T, et al. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ. 2009;180(11):E62–71. doi:10.1503/cmaj.090470
   PubMed Web of Science ®Google Scholar
• Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesis stimulating agents and mortality in patients with cancer: a meta-analysis of randomized trials. Lancet. 2009;373(9674):1532–1542. doi:10.1016/S0140-6736(09)60502-X
   PubMed Web of Science ®Google Scholar
• Aapro M, Osterwalder B, Scherhag A, Burger HU. Epoetin-beta treatment in patients with cancer chemotherapy-induced anaemia: the impact of initial haemoglobin and target haemoglobin levels on survival, tumour progression and thromboembolic events. Br J Cancer. 2009;101(12):1961–1971. doi:10.1038/sj.bjc.6605255
   PubMed Web of Science ®Google Scholar
• Bohlius J, Schmidlin K, Brillant C, et al. Erythropoietin or Darbepoetin for patients with cancer: meta-analysis based on individual patient data. Cochrane Database Syst Rev. 2009;2009(3):CD007303.
   Google Scholar
• Lyman GH, Bohlke K, Khorana AA, et al.; American Society of Clinical Oncology. Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. J Clin Oncol. 2015;33(6):654–656. doi:10.1200/JCO.2014.59.7351
   PubMed Web of Science ®Google Scholar
• Donnellan E, Khorana AA. Cancer and venous thromboembolic disease: a review. Oncologist. 2017;22(2):199–207. doi:10.1634/theoncologist.2016-0214
   PubMed Web of Science ®Google Scholar
• Jelkmann W, Bohlius J, Hallek M, Sytkowski AJ. The erythropoietin receptor in normal and cancer tissues. Crit Rev Oncol Hematol. 2008;67(1):39–61.
   PubMed Web of Science ®Google Scholar
• Sinclair AM, Todd MD, Forsythe K, Knox SJ, Elliott S, Begley CG. Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients. Cancer. 2007;110(3):477–488. doi:10.1002/cncr.22832
   Web of Science ®Google Scholar
• Glaspy J, Crawford J, Vansteenkiste J, et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer. 2010;102(2):301–315. doi:10.1038/sj.bjc.6605498
   PubMed Web of Science ®Google Scholar
• Engert A, Josting A, Haverkamp H, et al. Epoetin alfa in patients with advanced-stage Hodgkin’s lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. J Clin Oncol. 2010;28(13):2239–2245. doi:10.1200/JCO.2009.25.1835
   PubMed Web of Science ®Google Scholar
• Nitz U, Gluz O, Zuna I, et al. West German Study Group. Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer. Ann Oncol. 2014;25(1):75–80. doi:10.1093/annonc/mdt505
   Web of Science ®Google Scholar
• Pirker R, Ramlau RA, Schuette W, et al. Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide. J Clin Oncol. 2008;26(14):2342–2349. doi:10.1200/JCO.2007.15.0748
   Web of Science ®Google Scholar
• McKoy JM, Stonecash RE, Cournoyer D, et al. Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion. 2008;48(8):1754–1762. doi:10.1111/j.1537-2995.2008.01749.x
   PubMed Web of Science ®Google Scholar
• Bohlius J, Bohlke K, Castelli R, et al. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. Blood Adv. 2019;3(8):1197–1210. doi:10.1182/bloodadvances.2018030387
   Web of Science ®Google Scholar
• Abdel-Razeq H, Hashem H. Recent update in the pathogenesis and treatment of chemotherapy and cancer induced anemia. Crit Rev Oncol Hematol. 2020;145:102837. doi:10.1016/j.critrevonc.2019.102837
   PubMed Web of Science ®Google Scholar
• Weiss G, Ganz T, Goodnough LT. Anemia of inflammation. Blood. 2019;133(1):40–50. doi:10.1182/blood-2018-06-856500
   PubMed Web of Science ®Google Scholar
• Toblli JE, Angerosa M. Optimizing iron delivery in the management of anemia: patient considerations and the role of ferric carboxymaltose. Drug Des Dev Ther. 2014;8:2475–2491. doi:10.2147/DDDT.S55499
   PubMed Web of Science ®Google Scholar
• Baribeault D, Auerbach M. Iron replacement therapy in cancer-related anemia. Am J Health Syst Pharm. 2011;68(10 Suppl 1):S4–S14. doi:10.2146/ajhp110039
   Web of Science ®Google Scholar
• Mhaskar R, Wao H, Miladinovic B, Kumar A, Djulbegovic B. The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis stimulating agents. Cochrane Database Syst Rev. 2016;2:CD009624. doi:10.1002/14651858.CD009624.pub2
   PubMed Web of Science ®Google Scholar
• Auerbach M, Silberstein PT, Webb RT, et al. Darbepoetin alfa 300 or 500 mg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. Am J Hematol. 2010;85(9):655–663. doi:10.1002/ajh.21779
   Web of Science ®Google Scholar
• Bastit L, Vandebroek A, Altintas S, et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol. 2008;26(10):1611–1618. doi:10.1200/JCO.2006.10.4620
   Web of Science ®Google Scholar
• Gafter-Gvili A, Rozen-Zvi B, Vidal L, et al. Intravenous iron supplementation for the treatment of chemotherapy anaemia: systematic review and meta-analysis of randomized controlled studies. Acta Oncol. 2013;52(1):18–29. doi:10.3109/0284186X.2012.702921
   PubMed Web of Science ®Google Scholar
• Steensma DP, Sloan JA, Dakhil SR, et al. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. J Clin Oncol. 2011;29(1):97–105. doi:10.1200/JCO.2010.30.3644
   Web of Science ®Google Scholar
• Jang JH, Kim Y, Park S, et al. Efficacy of intravenous iron treatment for chemotherapy-induced anemia: a prospective phase II pilot clinical trial in South Korea. Plos Med. 2020;17(6):e1003091. doi:10.1371/journal.pmed.1003091
   PubMed Web of Science ®Google Scholar
• Steensma DP, Sasu BJ, Sloan JA, Tomita DK, Loprinzi CL. Serum hepcidin levels predict response to intravenous iron and darbepoetin in chemotherapy-associated anemia. Blood. 2015;125(23):3669–3671. doi:10.1182/blood-2015-03-636407
   Web of Science ®Google Scholar
• Gozzelino R, Arosio P. Iron homeostasis in health and disease. Int J Mol Sci. 2016;17(1):130. doi:10.3390/ijms17010130
   PubMed Web of Science ®Google Scholar
• González-Chávez SA, Arévalo-Gallegos S, Rascón-Cruz Q. Lactoferrin: structure, function and applications. Int J Antimicrob Agents. 2009;33(4):301.e1–8. doi:10.1016/j.ijantimicag.2008.07.020
   Web of Science ®Google Scholar
• Macciò A, Madeddu C, Gramignano G, Mulas C, Sanna E, Mantovani G. Efficacy and safety of oral lactoferrin supplementation in combination with rHuEPO-b for the treatment of anemia in advanced cancer patients undergoing chemotherapy: open-label, randomized controlled study. Oncologist. 2010;15(8):894–902. doi:10.1634/theoncologist.2010-0020
   Web of Science ®Google Scholar
• Cooke KS, Hinkle B, Salimi-Moosavi H, et al. A fully human anti-hepcidin antibody modulates iron metabolism in both mice and nonhuman primates. Blood. 2013;122(17):3054–3061. doi:10.1182/blood-2013-06-505792
   PubMed Web of Science ®Google Scholar
• Vadhan-Raj S, Abonour R, Goldman JW, et al. A first-in-human Phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. J Hematol Oncol. 2017;10(1):73. doi:10.1186/s13045-017-0427-x
   PubMed Web of Science ®Google Scholar
• Park EJ, Choi J, Lee KC, Na DH. Emerging PEGylated non-biologic drugs. Expert Opin Emerg Drugs. 2019;24(2):107–119. doi:10.1080/14728214.2019.1604684
   PubMed Web of Science ®Google Scholar
• Georgiev P, Lazarolu M, Ocroteala L, et al. The anti-hepcidin Spiegelmer Lexapeptid Pegol (NOX-H94) as treatment of anemia of chronic disease in patients with multiple myeloma, low grade lymphoma and CLL: a phase II pilot study. AACR Meeting; 2014:Abstract 3847.
   Google Scholar
• Haase VH. Therapeutic targeting of the HIF oxygen-sensing pathway: lessons learned from clinical studies. Exp Cell Res. 2017;356(2):160–165. doi:10.1016/j.yexcr.2017.05.004
   Web of Science ®Google Scholar
• Forristal CE, Levesque JP. Targeting the hypoxia-sensing pathway in clinical hematology. Stem Cell Transl Med. 2014;3(2):135–140. doi:10.5966/sctm.2013-0134
   PubMed Web of Science ®Google Scholar
• Wan J, Chai H, Yu Z, et al. HIF-1α effects on angiogenic potential in human small cell lung carcinoma. J Exp Clin Cancer Res. 2011;30(1):77. doi:10.1186/1756-9966-30-77
   Web of Science ®Google Scholar
• Seeley TW, Sternlicht MD, Klaus SJ, Neff TB, Liu DY. Induction of erythropoiesis by hypoxia-inducible factor prolyl hydroxylase inhibitors without promotion of tumor initiation, progression, or metastasis in a VEGF-sensitive model of spontaneous breast cancer. Hypoxia (Auckl). 2017;5:1–9. doi:10.2147/HP.S130526
   PubMed Web of Science ®Google Scholar
• Bayliss TJ, Smith JT, Schuster M, Dragnev KH, Rigas JR. A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert Opin Biol Ther. 2011;11(12):1663–1668. doi:10.1517/14712598.2011.627850
   PubMed Web of Science ®Google Scholar
• Coward J, Kulbe H, Chakravarty P, et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res. 2011;17(18):6083–6096. doi:10.1158/1078-0432.CCR-11-0945
   PubMed Web of Science ®Google Scholar
• Pauklin S, Vallier L. Activin/nodal signaling in stem cells. Development. 2015;142(4):607–619. doi:10.1242/dev.091769
   Web of Science ®Google Scholar
• Miller KL, Carlino JA, Ogawa Y, Avis PD, Carroll KG. Alterations in erythropoiesis in TGF-b 1-treated mice. Exp Hematol. 1992;20(8):951–956.
   Web of Science ®Google Scholar
• Kang YJ, Shin JW, Yoon JH, et al. Inhibition of erythropoiesis by Smad6 in human cord blood hematopoietic stem cells. Biochem Biophys Res Commun. 2011;423(4):750–756. doi:10.1016/j.bbrc.2012.06.031
   Web of Science ®Google Scholar
• Brancaleoni V, Nava I, Delbini P, Duca L, Motta I. Activin receptor-ligand trap for the treatment of β-thalassemia: a serendipitous discovery. Mediterr J Hematol Infect Dis. 2020;12(1):e2020075. doi:10.4084/mjhid.2020.075
   Web of Science ®Google Scholar
• Testa U, Castelli G, Elvira P. Experimental and investigational therapies for chemotherapy-induced anemia. Expert Opin Investig Drugs. 2015;24(11):1433–1445. doi:10.1517/13543784.2015.1085505
   PubMed Web of Science ®Google Scholar
• Patel B, Moosavi L. Luspatercept. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing LLC; July 10, 2020.
   Google Scholar
• Fenaux P, Kiladjian JJ, Platzbecker U. Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis. Blood. 2019;133(8):790–794. doi:10.1182/blood-2018-11-876888
   PubMed Web of Science ®Google Scholar
• Fenaux P, Platzbecker U, Mufti GJ, et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med. 2020;382(2):140–151. doi:10.1056/NEJMoa1908892
   PubMed Web of Science ®Google Scholar
• Kubasch AS, Fenaux P, Platzbecker U. Development of luspatercept to treat ineffective erythropoiesis. Blood Adv. 2021;5(5):1565–1575. doi:10.1182/bloodadvances.2020002177
   PubMed Web of Science ®Google Scholar
• Feld J, Navada SC, Silverman LR. Myelo-deception: luspatercept & TGF-Beta ligand traps in myeloid diseases & anemia. Leuk Res. 2020;97:106430. doi:10.1016/j.leukres.2020.106430
   PubMed Web of Science ®Google Scholar
• Raftopoulos H, Laadem A, Hesketh PJ, et al. Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two Phase 2 studies. Support Care Cancer. 2016;24(4):1517–1525. doi:10.1007/s00520-015-2929-9
   PubMed Web of Science ®Google Scholar
• Layer G, Reichelt J, Jahn D, Heinz DW. Structure and function of enzymes in heme biosynthesis. Protein Sci. 2010;19(6):1137–1161. doi:10.1002/pro.405
   PubMed Web of Science ®Google Scholar
• Madeddu C, Mantovani G, Gramignano G, Astara G, Macciò A. Muscle wasting as main evidence of energy impairment in cancer cachexia: future therapeutic approaches. Future Oncol. 2015;11(19):2697–2710. doi:10.2217/fon.15.195
   Web of Science ®Google Scholar
• Friesen DE, Baracos VE, Tuszynski JA. Modeling the energetic cost of cancer as a result of altered energy metabolism: implications for cachexia. Theor Biol Med Model. 2015;12:17. doi:10.1186/s12976-015-0015-0
   Web of Science ®Google Scholar
• Santino A, Scarano A, De Santis S, De Benedictis M, Giovinazzo G, Chieppa M. Gut microbiota modulation and anti-inflammatory properties of dietary polyphenols in IBD: new and consolidated perspectives. Curr Pharm Des. 2017;23(16):2344–2351. doi:10.2174/1381612823666170207145420
   Web of Science ®Google Scholar
• Rahman I, Biswas SK, Kirkham PA. Regulation of inflammation and redox signaling by dietary polyphenols. Biochem Pharmacol. 2006;72(11):1439–1452. doi:10.1016/j.bcp.2006.07.004
   PubMed Web of Science ®Google Scholar
• Yahfoufi N, Alsadi N, Jambi M, Matar C. The Immunomodulatory and anti-inflammatory role of polyphenols. Nutrients. 2018;10(11):1618. doi:10.3390/nu10111618
   PubMed Web of Science ®Google Scholar
• Fatih N, Camberlein E, Island ML, et al. Natural and synthetic STAT3 inhibitors reduce hepcidin expression in differentiated mouse hepatocytes expressing the active phosphorylated STAT3 form. J Mol Med (Berl). 2010;88(5):477–486. doi:10.1007/s00109-009-0588-3
   PubMed Web of Science ®Google Scholar
• Lainé F, Laviolle B, Bardou-Jacquet E, et al. Curcuma decreases serum hepcidin levels in healthy volunteers: a placebo-controlled, randomized, double-blind, cross-over study. Fundam Clin Pharm. 2017;31(5):567–573. doi:10.1111/fcp.12288
   PubMed Web of Science ®Google Scholar
• Jiao Y, Wilkinson J, Di X, et al. Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator. Blood. 2009;113(2):462–469. doi:10.1182/blood-2008-05-155952
   PubMed Web of Science ®Google Scholar
• Mohammadi E, Tamaddoni A, Qujeq D, et al. An investigation of the effects of curcumin on iron overload, hepcidin level, and liver function in β-thalassemia major patients: a double-blind randomized controlled clinical trial. Phytother Res. 2018;32(9):1828–1835. doi:10.1002/ptr.6118
   PubMed Web of Science ®Google Scholar
• Macciò A, Gramignano G, Madeddu C. A multitargeted treatment approach for anemia and cachexia in metastatic castration-resistant prostate cancer. J Pain Symptom Manage. 2015;50(2):e1–e4. doi:10.1016/j.jpainsymman.2015.04.014
   Web of Science ®Google Scholar
• Macciò A, Gramignano G, Madeddu C. Surprising results of a supportive integrated therapy in myelofibrosis. Nutrition. 2015;31(1):239–243. doi:10.1016/j.nut.2014.07.016
   Web of Science ®Google Scholar
• Endo K, Tsuji A, Kondo S, Wakisaka N, Murono S, Yoshizaki T. Carnitine is associated with fatigue following chemoradiotherapy for head and neck cancer. Acta Otolaryngol. 2015;135(8):846–852. doi:10.3109/00016489.2015.1030769
   PubMed Web of Science ®Google Scholar
• Hockenberry MJ, Hooke MC, Gregurich M, McCarthy K. Carnitine plasma levels and fatigue in children/adolescents receiving cisplatin, ifosfamide, or doxorubicin. J Pediatr Hematol Oncol. 2009;31(9):664–669. doi:10.1097/MPH.0b013e3181b259a7
   Web of Science ®Google Scholar
• Cruciani RA, Dvorkin E, Homel P, et al. L-carnitine supplementation in patients with advanced cancer and carnitine deficiency: a double-blind, placebo-controlled study. J Pain Symptom Manage. 2009;37(4):622–631. doi:10.1016/j.jpainsymman.2008.03.021
   Web of Science ®Google Scholar
• Morris MS, Jacques PF, Rosenberg IH, Selhub J. Folate and vitamin B-12 status in relation to anemia, macrocytosis, and cognitive impairment in older Americans in the age of folic acid fortification. Am J Clin Nutr. 2007;85(1):193–200. doi:10.1093/ajcn/85.1.193
   PubMed Web of Science ®Google Scholar
• Lonsdale D. A review of the biochemistry, metabolism and clinical benefits of thiamin(e) and its derivatives. Evid Based Complement Alternat Med. 2006;3(1):49–59. doi:10.1093/ecam/nek009
   PubMed Web of Science ®Google Scholar
• Parra M, Stahl S, Hellmann H. Vitamin B₆ and its role in cell metabolism and physiology. Cells. 2018;7(7):84. doi:10.3390/cells7070084
   PubMed Web of Science ®Google Scholar
• Smith EM, Tangpricha V. Vitamin D and anemia: insights into an emerging association. Curr Opin Endocrinol Diabetes Obes. 2015;22(6):432–438. doi:10.1097/MED.0000000000000199
   Google Scholar
• Zughaier SM, Alvarez JA, Sloan JH, Konrad RJ, Tangpricha V. The role of vitamin D in regulating the iron-hepcidin-ferroportin axis in monocytes. J Clin Transl Endocrinol. 2014;1(1):19–25. doi:10.1016/j.jcte.2014.01.003
   Google Scholar
• Perlstein TS, Pande R, Berliner N, Vanasse GJ. Prevalence of 25-hydroxyvitamin D deficiency in subgroups of elderly persons with anemia: association with anemia of inflammation. Blood. 2011;117(10):2800–2806. doi:10.1182/blood-2010-09-309708
   Web of Science ®Google Scholar
• Icardi A, Paoletti E, De Nicola L, Mazzaferro S, Russo R, Cozzolino M. Renal anaemia and EPO hyporesponsiveness associated with vitamin D deficiency: the potential role of inflammation. Nephrol Dial Transplant. 2013;28(7):1672–1679. doi:10.1093/ndt/gft021
   PubMed Web of Science ®Google Scholar
• Smith EM, Alvarez JA, Kearns MD, et al. High-dose vitamin D3 reduces circulating hepcidin concentrations: a pilot, randomized, double-blind, placebo-controlled trial in healthy adults. Clin Nutr. 2017;36(4):980–985. doi:10.1016/j.clnu.2016.06.015
   Web of Science ®Google Scholar
• Moran-Lev H, Galai T, Yerushalmy-Feler A, et al. Vitamin D decreases hepcidin and inflammatory markers in newly diagnosed inflammatory bowel disease paediatric patients: a Prospective Study. J Crohn’s Colitis. 2019;13(10):1287–1291. doi:10.1093/ecco-jcc/jjz056
   Google Scholar
• Pasini E, Corsetti G, Romano C, et al. Management of anaemia of chronic disease: beyond iron-only supplementation. Nutrients. 2021;13(1):237. doi:10.3390/nu13010237
   Web of Science ®Google Scholar
• Hallberg L, Brune M, Rossander L. Iron absorption in man: ascorbic acid and dose-dependent inhibition by phytate. Am J Clin Nutr. 1989;49(1):140–144. doi:10.1093/ajcn/49.1.140
   PubMed Web of Science ®Google Scholar
• Lane DJ, Richardson DR. The active role of vitamin C in mammalian iron metabolism: much more than just enhanced iron absorption! Free Radic Biol Med. 2014;75:69–83. doi:10.1016/j.freeradbiomed.2014.07.007
   PubMed Web of Science ®Google Scholar
• Chiu PF, Ko SY, Chang CC. Vitamin C affects the expression of hepcidin and erythropoietin receptor in HepG2 cells. J Ren Nutr. 2012;22(3):373–376. doi:10.1053/j.jrn.2011.09.007
   PubMed Web of Science ®Google Scholar
• Attallah N, Osman-Malik Y, Frinak S, Besarab A. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia. Am J Kidney Dis. 2006;47(4):644–654. doi:10.1053/j.ajkd.2005.12.025
   PubMed Web of Science ®Google Scholar
• Barni S, Gascòn P, Petrelli F, et al. Position paper on management of iron deficiency in adult cancer patients. Expert Rev Hematol. 2017;10(8):685–695. doi:10.1080/17474086.2017.1343140
   PubMed Web of Science ®Google Scholar
• Steinmetz T, Tschechne B, Harlin O, et al. Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. Ann Oncol. 2013;24(2):475–482. doi:10.1093/annonc/mds338
   PubMed Web of Science ®Google Scholar
• Toledano A, Luporsi E, Morere JF, et al. Clinical use of ferric carboxymaltose in patients with solid tumours or haematological malignancies in France. Support Care Cancer. 2016;24(1):67–75. doi:10.1007/s00520-015-2728-3
   PubMed Web of Science ®Google Scholar